{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:29:46Z","timestamp":1773898186408,"version":"3.50.1"},"reference-count":229,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T00:00:00Z","timestamp":1645920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T00:00:00Z","timestamp":1645920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12325-022-02070-z","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T16:02:17Z","timestamp":1645977737000},"page":"1524-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic Advances in Viral Hepatitis\u00a0A\u2013E"],"prefix":"10.1007","volume":"39","author":[{"given":"Navroop","family":"Nagra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Kozarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blaire E.","family":"Burman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,27]]},"reference":[{"key":"2070_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1128\/CMR.14.1.38-58.2001","volume":"14","author":"JA Cuthbert","year":"2001","unstructured":"Cuthbert JA. Hepatitis\u00a0A: old and new. Clin Microbiol Rev. 2001;14:38\u201358. https:\/\/doi.org\/10.1128\/CMR.14.1.38-58.2001.","journal-title":"Clin Microbiol Rev"},{"key":"2070_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.15585\/mmwr.mm6818a2","volume":"68","author":"MA Foster","year":"2019","unstructured":"Foster MA, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis\u00a0A virus infections\u2014United States, 2013\u20132018. Morb Mortal Wkly Rep. 2019;68:413\u20135. https:\/\/doi.org\/10.15585\/mmwr.mm6818a2.","journal-title":"Morb Mortal Wkly Rep"},{"key":"2070_CR3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.15585\/mmwr.mm6743a3","volume":"67","author":"M Foster","year":"2018","unstructured":"Foster M, Ramachandran S, Myatt K, et al. Hepatitis\u00a0A virus outbreaks associated with drug use and homelessness\u2014California, Kentucky, Michigan, and Utah, 2017. Morb Mortal Wkly Rep. 2018;67:1208\u201310. https:\/\/doi.org\/10.15585\/mmwr.mm6743a3.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"2 Suppl 1","key":"2070_CR4","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1002\/hep.21052","volume":"43","author":"A Martin","year":"2006","unstructured":"Martin A, Lemon SM. Hepatitis\u00a0A virus: from discovery to vaccines. Hepatology. 2006;43(2 Suppl 1):S164\u201372. https:\/\/doi.org\/10.1002\/hep.21052.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"2070_CR5","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/0264-410x(92)90536-s","volume":"10","author":"JL Melnick","year":"1992","unstructured":"Melnick JL. Properties and classification of hepatitis\u00a0A virus. Vaccine. 1992;10(Suppl 1):S24\u20136. https:\/\/doi.org\/10.1016\/0264-410x(92)90536-s.","journal-title":"Vaccine"},{"key":"2070_CR6","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1099\/jgv.0.000911","volume":"98","author":"R Zell","year":"2017","unstructured":"Zell R, Delwart E, Gorbalenya AE, et al. ICTV virus taxonomy profile: picornaviridae. J Gen Virol. 2017;98:2421\u20132. https:\/\/doi.org\/10.1099\/jgv.0.000911.","journal-title":"J Gen Virol"},{"key":"2070_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/infdis\/154.2.231","volume":"154","author":"NC Tassopoulos","year":"1986","unstructured":"Tassopoulos NC, Papaevangelou GJ, Ticehurst JR, Purcell RH. Fecal excretion of Greek strains of hepatitis\u00a0A virus in patients with hepatitis\u00a0A and in experimentally infected chimpanzees. J Infect Dis. 1986;154:231\u20137. https:\/\/doi.org\/10.1093\/infdis\/154.2.231.","journal-title":"J Infect Dis"},{"key":"2070_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1537-2995.1998.38698326337.x","volume":"38","author":"JM Soucie","year":"1998","unstructured":"Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis\u00a0A virus infections associated with clotting factor concentrate in the United States. Transfusion. 1998;38:573\u20139. https:\/\/doi.org\/10.1046\/j.1537-2995.1998.38698326337.x.","journal-title":"Transfusion"},{"issue":"4 Suppl 9","key":"2070_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0037-1963(01)90132-5","volume":"38","author":"RJ Benjamin","year":"2001","unstructured":"Benjamin RJ. Nucleic acid testing: update and applications. Semin Hematol. 2001;38(4 Suppl 9):11\u20136. https:\/\/doi.org\/10.1016\/s0037-1963(01)90132-5.","journal-title":"Semin Hematol"},{"key":"2070_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/oxfordjournals.aje.a114093","volume":"122","author":"WM Lednar","year":"1985","unstructured":"Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis\u00a0A virus infections in adults. Am J Epidemiol. 1985;122:226\u201333. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114093.","journal-title":"Am J Epidemiol"},{"issue":"Suppl 1","key":"2070_CR11","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/infdis\/171.supplement_1.s15","volume":"171","author":"MJ Tong","year":"1995","unstructured":"Tong MJ, El-Farra NS, Grew MI. Clinical manifestations of hepatitis\u00a0A: recent experience in a community teaching hospital. J Infect Dis. 1995;171(Suppl 1):S15-18. https:\/\/doi.org\/10.1093\/infdis\/171.supplement_1.s15.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"2070_CR12","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/0264-410x(92)90533-p","volume":"10","author":"RS Koff","year":"1992","unstructured":"Koff RS. Clinical manifestations and diagnosis of hepatitis\u00a0A virus infection. Vaccine. 1992;10(Suppl 1):S15-17. https:\/\/doi.org\/10.1016\/0264-410x(92)90533-p.","journal-title":"Vaccine"},{"key":"2070_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/s0891-5520(05)70123-9","volume":"14","author":"NM Kemmer","year":"2000","unstructured":"Kemmer NM, Miskovsky EP. Hepatitis\u00a0A. Infect Dis Clin North Am. 2000;14:605\u201315. https:\/\/doi.org\/10.1016\/s0891-5520(05)70123-9.","journal-title":"Infect Dis Clin North Am"},{"key":"2070_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00006454-200104000-00004","volume":"20","author":"M Richardson","year":"2001","unstructured":"Richardson M, Elliman D, Maguire H, Simpson J, Nicoll A. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J. 2001;20:380\u201391. https:\/\/doi.org\/10.1097\/00006454-200104000-00004.","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 1","key":"2070_CR15","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/0264-410x(92)90534-q","volume":"10","author":"ER Schiff","year":"1992","unstructured":"Schiff ER. Atypical clinical manifestations of hepatitis\u00a0A. Vaccine. 1992;10(Suppl 1):S18-20. https:\/\/doi.org\/10.1016\/0264-410x(92)90534-q.","journal-title":"Vaccine"},{"key":"2070_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00005792-199201000-00002","volume":"71","author":"M Glikson","year":"1992","unstructured":"Glikson M, Galun E, Oren R, Tur-Kaspa R, Shouval D. Relapsing hepatitis\u00a0A. Review of 14 cases and literature survey. Medicine (Baltimore). 1992;71:14\u201323. https:\/\/doi.org\/10.1097\/00005792-199201000-00002.","journal-title":"Medicine (Baltimore)"},{"key":"2070_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/infdis\/jiv417%JTheJournalofInfectiousDiseases","volume":"213","author":"E Tennant","year":"2015","unstructured":"Tennant E, Post JJ. Production of false-positive immunoglobulin M antibodies to hepatitis\u00a0A virus in autoimmune events. J Infect Dis. 2015;213:324\u20135. https:\/\/doi.org\/10.1093\/infdis\/jiv417%JTheJournalofInfectiousDiseases.","journal-title":"J Infect Dis"},{"key":"2070_CR18","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/trf.12648","volume":"54","author":"JA Hughes","year":"2014","unstructured":"Hughes JA, Fontaine MJ, Gonzalez CL, Layon AG, Goodnough LT, Galel SA. Case report of a transfusion-associated hepatitis\u00a0A infection. Transfusion. 2014;54:2202\u20136. https:\/\/doi.org\/10.1111\/trf.12648.","journal-title":"Transfusion"},{"key":"2070_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI103164","volume":"34","author":"TC Chalmers","year":"1955","unstructured":"Chalmers TC, Eckhardt RD, Reynolds WE, et al. The treatment of acute infectious hepatitis. Controlled studies of the effects of diet, rest, and physical reconditioning on the acute course of the disease and on the incidence of relapses and residual abnormalities. J Clin Investig. 1955;34:1163\u2013235. https:\/\/doi.org\/10.1172\/JCI103164.","journal-title":"J Clin Investig"},{"key":"2070_CR20","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.3748\/wjg.v9.i12.2698","volume":"9","author":"H Gunduz","year":"2003","unstructured":"Gunduz H, Karabay O, Tamer A, Ozaras R, Mert A, Tabak OF. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003;9:2698\u2013700. https:\/\/doi.org\/10.3748\/wjg.v9.i12.2698.","journal-title":"World J Gastroenterol"},{"key":"2070_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0166-3542(95)00039-o","volume":"28","author":"JM Crance","year":"1995","unstructured":"Crance JM, Leveque F, Chousterman S, Jouan A, Trepo C, Deloince R. Antiviral activity of recombinant interferon-alpha on hepatitis\u00a0A virus replication in human liver cells. Antiviral Res. 1995;28:69\u201380. https:\/\/doi.org\/10.1016\/0166-3542(95)00039-o.","journal-title":"Antiviral Res"},{"key":"2070_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/s0140-6736(94)91132-0","volume":"343","author":"M Yoshiba","year":"1994","unstructured":"Yoshiba M, Inoue K, Sekiyama K. Interferon for hepatitis\u00a0A. Lancet. 1994;343:288\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(94)91132-0.","journal-title":"Lancet"},{"key":"2070_CR23","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1093\/nar\/gkr1152%JNucleicAcidsResearch","volume":"40","author":"BS Blaum","year":"2011","unstructured":"Blaum BS, W\u00fcnsche W, Benie AJ, et al. Functional binding of hexanucleotides to 3C protease of hepatitis\u00a0A virus. Nucleic Acids Res. 2011;40:3042\u201355. https:\/\/doi.org\/10.1093\/nar\/gkr1152%JNucleicAcidsResearch.","journal-title":"Nucleic Acids Res"},{"key":"2070_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.bbrc.2015.02.058","volume":"458","author":"X Jiang","year":"2015","unstructured":"Jiang X, Kanda T, Nakamoto S, et al. The JAK2 inhibitor AZD1480 inhibits hepatitis\u00a0A virus replication in Huh7 cells. Biochem Biophys Res Commun. 2015;458:908\u201312. https:\/\/doi.org\/10.1016\/j.bbrc.2015.02.058.","journal-title":"Biochem Biophys Res Commun"},{"key":"2070_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/omcr\/omz080","volume":"8","author":"D Daghman","year":"2019","unstructured":"Daghman D, Rez MS, Soltany A, Alsaleh A. Two case reports of corticosteroid administration-prolonged and pulsed therapy-in treatment of pruritus in cholestatic hepatitis\u00a0A patients. Oxf Med Case Rep. 2019;8:25. https:\/\/doi.org\/10.1093\/omcr\/omz080.","journal-title":"Oxf Med Case Rep"},{"issue":"2","key":"2070_CR26","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.jceh.2017.05.063","volume":"7","author":"PD Ganga","year":"2017","unstructured":"Ganga PD, Reddy V, Joseph TS, et al. Role of steroids in cholestatic viral hepatitis\u00a0A and E. J Clin Exp Hepatol. 2017;7(2):S30\u20131. https:\/\/doi.org\/10.1016\/j.jceh.2017.05.063.","journal-title":"J Clin Exp Hepatol"},{"key":"2070_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.15585\/mmwr.mm6806a6","volume":"68","author":"M Doshani","year":"2019","unstructured":"Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for use of hepatitis\u00a0A vaccine for persons experiencing homelessness. Morb Mortal Wkly Rep. 2019;68:153\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm6806a6.","journal-title":"Morb Mortal Wkly Rep"},{"key":"2070_CR28","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.15585\/mmwr.mm6743a5","volume":"67","author":"NP Nelson","year":"2018","unstructured":"Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: recommendations of the Advisory Committee on Immunization Practices for use of hepatitis\u00a0A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel. Morb Mortal Wkly Rep. 2018;67:1216\u201320. https:\/\/doi.org\/10.15585\/mmwr.mm6743a5.","journal-title":"Morb Mortal Wkly Rep"},{"key":"2070_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6905a1","volume":"69","author":"NP Nelson","year":"2020","unstructured":"Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis\u00a0A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69:1\u201338. https:\/\/doi.org\/10.15585\/mmwr.rr6905a1.","journal-title":"MMWR Recomm Rep"},{"key":"2070_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/hep.28109","volume":"63","author":"H Roberts","year":"2016","unstructured":"Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis\u00a0B virus (HBV) infection in US households: National Health and Nutrition Examination Survey (NHANES), 1988\u20132012. Hepatology. 2016;63:388\u201397. https:\/\/doi.org\/10.1002\/hep.28109.","journal-title":"Hepatology"},{"key":"2070_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cld.2018.06.002","volume":"22","author":"KR Mysore","year":"2018","unstructured":"Mysore KR, Leung DH. Hepatitis\u00a0B and C. Clin Liver Dis. 2018;22:703\u201322. https:\/\/doi.org\/10.1016\/j.cld.2018.06.002.","journal-title":"Clin Liver Dis"},{"key":"2070_CR32","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1128\/jcm.40.4.1207-1209.2002","volume":"40","author":"JH Kao","year":"2002","unstructured":"Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis\u00a0B virus in patients with chronic hepatitis\u00a0B virus infection. J Clin Microbiol. 2002;40:1207\u20139. https:\/\/doi.org\/10.1128\/jcm.40.4.1207-1209.2002.","journal-title":"J Clin Microbiol"},{"key":"2070_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jmv.1051","volume":"64","author":"PD Swenson","year":"2001","unstructured":"Swenson PD, Van Geyt C, Alexander ER, et al. Hepatitis\u00a0B virus genotypes and HBsAg subtypes in refugees and injection drug users in the United States determined by LiPA and monoclonal EIA. J Med Virol. 2001;64:305\u201311. https:\/\/doi.org\/10.1002\/jmv.1051.","journal-title":"J Med Virol"},{"key":"2070_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jhin.2006.06.029","volume":"64","author":"K Kidd-Ljunggren","year":"2006","unstructured":"Kidd-Ljunggren K, Holmberg A, Blackberg J, Lindqvist B. High levels of hepatitis\u00a0B virus DNA in body fluids from chronic carriers. J Hosp Infect. 2006;64:352\u20137. https:\/\/doi.org\/10.1016\/j.jhin.2006.06.029.","journal-title":"J Hosp Infect"},{"key":"2070_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/infdis\/146.2.198","volume":"146","author":"RP Beasley","year":"1982","unstructured":"Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis\u00a0B virus infections in preschool children in Taiwan. J Infect Dis. 1982;146:198\u2013204. https:\/\/doi.org\/10.1093\/infdis\/146.2.198.","journal-title":"J Infect Dis"},{"key":"2070_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.15585\/mmwr.mm6503a2","volume":"65","author":"AM Harris","year":"2016","unstructured":"Harris AM, Iqbal K, Schillie S, et al. Increases in acute hepatitis\u00a0B virus infections\u2014Kentucky, Tennessee, and West Virginia, 2006\u20132013. Morb Mortal Wkly Rep. 2016;65:47\u201350. https:\/\/doi.org\/10.15585\/mmwr.mm6503a2.","journal-title":"Morb Mortal Wkly Rep"},{"key":"2070_CR37","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.transproceed.2004.12.041","volume":"37","author":"TM De Feo","year":"2005","unstructured":"De Feo TM, Poli F, Mozzi F, Moretti MP, Scalamogna M, Collaborative Kidney, Liver and Heart North Italy Transplant Program Study Groups. Risk of transmission of hepatitis\u00a0B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc. 2005;37:1238\u20139. https:\/\/doi.org\/10.1016\/j.transproceed.2004.12.041.","journal-title":"Transplant Proc"},{"key":"2070_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.annepidem.2009.01.017","volume":"19","author":"RP Beasley","year":"2009","unstructured":"Beasley RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol. 2009;19:231\u20134. https:\/\/doi.org\/10.1016\/j.annepidem.2009.01.017.","journal-title":"Ann Epidemiol"},{"key":"2070_CR39","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/0016-5085(87)90614-7","volume":"92","author":"NC Tassopoulos","year":"1987","unstructured":"Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis\u00a0B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92:1844\u201350. https:\/\/doi.org\/10.1016\/0016-5085(87)90614-7.","journal-title":"Gastroenterology"},{"key":"2070_CR40","first-page":"S46","volume":"35","author":"CY Lin","year":"1991","unstructured":"Lin CY. Clinical features and natural course of HBV-related glomerulopathy in children. Kidney Int Suppl. 1991;35:S46-53.","journal-title":"Kidney Int Suppl"},{"key":"2070_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0168-8278(90)90069-4","volume":"10","author":"AS Lok","year":"1990","unstructured":"Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis\u00a0B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol. 1990;10:29\u201334. https:\/\/doi.org\/10.1016\/0168-8278(90)90069-4.","journal-title":"J Hepatol"},{"key":"2070_CR42","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1056\/NEJMoa013215","volume":"347","author":"HI Yang","year":"2002","unstructured":"Yang HI, Lu SN, Liaw YF, et al. Hepatitis\u00a0B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168\u201374. https:\/\/doi.org\/10.1056\/NEJMoa013215.","journal-title":"N Engl J Med"},{"key":"2070_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk evaluation of viral load E, associated liver disease\/cancer-in hBVSG. Predicting cirrhosis risk based on the level of circulating hepatitis\u00a0B viral load. Gastroenterology. 2006;130:678\u201386. https:\/\/doi.org\/10.1053\/j.gastro.2005.11.016.","journal-title":"Gastroenterology"},{"key":"2070_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/hep.26041","volume":"57","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis\u00a0B surface antigen levels help predict disease progression in patients with low hepatitis\u00a0B virus loads. Hepatology. 2013;57:441\u201350. https:\/\/doi.org\/10.1002\/hep.26041.","journal-title":"Hepatology"},{"key":"2070_CR45","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"CCH Trepo","year":"2014","unstructured":"Trepo CCH, Lok A. Hepatitis\u00a0B virus infection. Lancet. 2014;384:2053\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(14)60220-8.","journal-title":"Lancet"},{"key":"2070_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis\u00a0B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2007.11.011.","journal-title":"J Hepatol"},{"key":"2070_CR47","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1055\/s-2006-939752","volume":"26","author":"CM Chu","year":"2006","unstructured":"Chu CM, Liaw YF. Hepatitis\u00a0B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26:142\u201352. https:\/\/doi.org\/10.1055\/s-2006-939752.","journal-title":"Semin Liver Dis"},{"key":"2070_CR48","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/jvh.13312","volume":"27","author":"WM Lee","year":"2020","unstructured":"Lee WM, King WC, Schwarz KB, Rule J, Lok ASF, HBRN Investigators. Prevalence and clinical features of patients with concurrent HBsAg and anti-HBs: evaluation of the hepatitis\u00a0B research network cohort. J Viral Hepat. 2020;27:922\u201331. https:\/\/doi.org\/10.1111\/jvh.13312.","journal-title":"J Viral Hepat"},{"key":"2070_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19803","author":"MM Sfeir","year":"2021","unstructured":"Sfeir MM, Snayd M. Serologic testing for hepatitis\u00a0B. JAMA. 2021. https:\/\/doi.org\/10.1001\/jama.2021.19803.","journal-title":"JAMA"},{"key":"2070_CR50","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","volume":"46","author":"G Raimondo","year":"2007","unstructured":"Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis\u00a0B virus infection. J Hepatol. 2007;46:160\u201370. https:\/\/doi.org\/10.1016\/j.jhep.2006.10.007.","journal-title":"J Hepatol"},{"key":"2070_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1440-1746.2012.07280.x","volume":"28","author":"W Yeo","year":"2013","unstructured":"Yeo W, Chan HL. Hepatitis\u00a0B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol. 2013;28:31\u20137. https:\/\/doi.org\/10.1111\/j.1440-1746.2012.07280.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"2070_CR52","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jhep.2020.04.015","volume":"73","author":"KLT Mouzannar","year":"2020","unstructured":"Mouzannar KLT. Hepatitis\u00a0B virus\u2014recent therapeutic advances and challenges to cure. J Hepatol. 2020;73:694\u20135. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.015.","journal-title":"J Hepatol"},{"key":"2070_CR53","doi-asserted-by":"publisher","first-page":"204993612096502","DOI":"10.1177\/2049936120965027","volume":"7","author":"V Soriano","year":"2020","unstructured":"Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis\u00a0B therapeutics. Ther Adv Infect Dis. 2020;7:2049936120965027. https:\/\/doi.org\/10.1177\/2049936120965027.","journal-title":"Ther Adv Infect Dis"},{"key":"2070_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","volume":"72","author":"M Cornberg","year":"2020","unstructured":"Cornberg M, Lok A, Terrault N, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis\u00a0B\u2014report from the 2019 EASL-AASLD HBV treatment endpoints conference. Hepatology. 2020;72:539\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.003.","journal-title":"Hepatology"},{"key":"2070_CR55","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","volume":"66","author":"K Giersch","year":"2017","unstructured":"Giersch K, Allweiss L, Volz T, Dandri M, L\u00fctgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66:460\u20132. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.028.","journal-title":"J Hepatol"},{"key":"2070_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/apt.14376","volume":"47","author":"LY Mak","year":"2018","unstructured":"Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis\u00a0B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis\u00a0B virus infection. Aliment Pharmacol Ther. 2018;47:43\u201354. https:\/\/doi.org\/10.1111\/apt.14376.","journal-title":"Aliment Pharmacol Ther"},{"key":"2070_CR57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3851\/IMP3280Erratum.In:AntivirTher.2019;24:151","volume":"24","author":"H Liao","year":"2019","unstructured":"Liao H, Liu Y, Li X, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside\/nucleotide analogue therapy. Antivir Ther. 2019;24:105\u201315. https:\/\/doi.org\/10.3851\/IMP3280Erratum.In:AntivirTher.2019;24:151.","journal-title":"Antivir Ther"},{"key":"2070_CR58","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1002\/hep.31616","volume":"73","author":"LY Mak","year":"2021","unstructured":"Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in patients with chronic hepatitis\u00a0B under different disease phases and antiviral therapy. Hepatology. 2021;73:2167\u201379. https:\/\/doi.org\/10.1002\/hep.31616.","journal-title":"Hepatology"},{"key":"2070_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/hep4.1281","volume":"3","author":"LA Suk-Fong","year":"2018","unstructured":"Suk-Fong LA. Hepatitis\u00a0B treatment: what we know now and what remains to be researched. Hepatol Commun. 2018;3:8\u201319. https:\/\/doi.org\/10.1002\/hep4.1281.","journal-title":"Hepatol Commun"},{"key":"2070_CR60","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","volume":"126","author":"B Werle-Lapostolle","year":"2004","unstructured":"Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis\u00a0B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2004.03.018.","journal-title":"Gastroenterology"},{"key":"2070_CR61","doi-asserted-by":"publisher","first-page":"a021501","DOI":"10.1101\/cshperspect.a021501","volume":"5","author":"F Zoulim","year":"2015","unstructured":"Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis\u00a0B. Cold Spring Harb Perspect Med. 2015;5:a021501. https:\/\/doi.org\/10.1101\/cshperspect.a021501.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2070_CR62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NABN Terrault","year":"2016","unstructured":"Terrault NABN, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis\u00a0B. Hepatology. 2016;63:261\u201383. https:\/\/doi.org\/10.1002\/hep.28156.","journal-title":"Hepatology"},{"key":"2070_CR63","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis\u00a0B: AASLD 2018 hepatitis\u00a0B guidance. Hepatology. 2018;67:1560\u201399. https:\/\/doi.org\/10.1002\/hep.29800.","journal-title":"Hepatology"},{"key":"2070_CR64","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis\u00a0B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503\u201314. https:\/\/doi.org\/10.1002\/hep.22841.","journal-title":"Hepatology"},{"key":"2070_CR65","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/apt.13440","volume":"43","author":"J Ahn","year":"2016","unstructured":"Ahn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis\u00a0B patients in the US\u2014the ENUMERATE study. Aliment Pharmacol Ther. 2016;43:134\u201344. https:\/\/doi.org\/10.1111\/apt.13440.","journal-title":"Aliment Pharmacol Ther"},{"key":"2070_CR66","doi-asserted-by":"publisher","first-page":"e00046","DOI":"10.1128\/CMR.00046-19","volume":"33","author":"MH Nguyen","year":"2020","unstructured":"Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis\u00a0B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33:e00046-e119. https:\/\/doi.org\/10.1128\/CMR.00046-19.","journal-title":"Clin Microbiol Rev"},{"key":"2070_CR67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3350\/cmh.2016.0045","volume":"22","author":"I Varbobitis","year":"2016","unstructured":"Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis\u00a0B under antiviral therapy. Clin Mol Hepatol. 2016;22:319\u201326. https:\/\/doi.org\/10.3350\/cmh.2016.0045.","journal-title":"Clin Mol Hepatol"},{"key":"2070_CR68","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/infdis\/jiv180","volume":"212","author":"F Stelma","year":"2015","unstructured":"Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, et al. Natural killer cell characteristics in patients with chronic hepatitis\u00a0B virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon alfa-2a and adefovir. J Infect Dis. 2015;212:1042\u201351. https:\/\/doi.org\/10.1093\/infdis\/jiv180.","journal-title":"J Infect Dis"},{"key":"2070_CR69","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1172\/JCI58847","volume":"122","author":"L Belloni","year":"2012","unstructured":"Belloni L, Allweiss L, Guerrieri F, et al. IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012;122:529\u201337. https:\/\/doi.org\/10.1172\/JCI58847.","journal-title":"J Clin Invest"},{"key":"2070_CR70","doi-asserted-by":"publisher","first-page":"9332","DOI":"10.1128\/JVI.00918-10","volume":"84","author":"C Xu","year":"2010","unstructured":"Xu C, Guo H, Pan XB, et al. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis\u00a0B virus. J Virol. 2010;84:9332\u201340. https:\/\/doi.org\/10.1128\/JVI.00918-10.","journal-title":"J Virol"},{"key":"2070_CR71","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","volume":"137","author":"EH Buster","year":"2009","unstructured":"Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis\u00a0B e antigen-positive chronic hepatitis\u00a0B to peginterferon-alfa. Gastroenterology. 2009;137:2002\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2009.08.061.","journal-title":"Gastroenterology"},{"key":"2070_CR72","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12072-007-9022-5","volume":"2","author":"T Piratvisuth","year":"2008","unstructured":"Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis\u00a0B. Hepatol Int. 2008;2:102\u201310. https:\/\/doi.org\/10.1007\/s12072-007-9022-5.","journal-title":"Hepatol Int"},{"key":"2070_CR73","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cld.2016.06.002","volume":"20","author":"MA Konerman","year":"2016","unstructured":"Konerman MA, Lok AS. Interferon treatment for hepatitis\u00a0B. Clin Liver Dis. 2016;20:645\u201365. https:\/\/doi.org\/10.1016\/j.cld.2016.06.002.","journal-title":"Clin Liver Dis"},{"key":"2070_CR74","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, et al. Peginterferon Alfa-2a H-NCHBSG. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis\u00a0B. N Engl J Med. 2004;351:1206\u201317. https:\/\/doi.org\/10.1056\/NEJMoa040431.","journal-title":"N Engl J Med"},{"key":"2070_CR75","doi-asserted-by":"publisher","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","volume":"142","author":"HL Chan","year":"2005","unstructured":"Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis\u00a0B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005;142:240\u201350. https:\/\/doi.org\/10.7326\/0003-4819-142-4-200502150-00006.","journal-title":"Ann Intern Med"},{"key":"2070_CR76","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s0140-6736(88)92355-0","volume":"2","author":"AS Lok","year":"1988","unstructured":"Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis\u00a0B infection. Lancet. 1988;2:298\u2013302. https:\/\/doi.org\/10.1016\/s0140-6736(88)92355-0.","journal-title":"Lancet"},{"key":"2070_CR77","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/s0140-6736(87)91371-7","volume":"2","author":"CL Lai","year":"1987","unstructured":"Lai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet. 1987;2:877\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(87)91371-7.","journal-title":"Lancet"},{"key":"2070_CR78","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/0016-5085(93)90281-g","volume":"104","author":"JH Hoofnagle","year":"1993","unstructured":"Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis\u00a0B. Gastroenterology. 1993;104:1116\u201321. https:\/\/doi.org\/10.1016\/0016-5085(93)90281-g.","journal-title":"Gastroenterology"},{"key":"2070_CR79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/00004836-200101000-00017","volume":"32","author":"JF Trotter","year":"2001","unstructured":"Trotter JF, Zygmunt AJ. Conception and pregnancy during interferon-alpha therapy for chronic hepatitis\u00a0C. J Clin Gastroenterol. 2001;32:76\u20138. https:\/\/doi.org\/10.1097\/00004836-200101000-00017.","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl 1","key":"2070_CR80","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/liv.12078","volume":"33","author":"G Dusheiko","year":"2013","unstructured":"Dusheiko G. Treatment of HBeAg positive chronic hepatitis\u00a0B: interferon or nucleoside analogues. Liver Int. 2013;33(Suppl 1):137\u201350. https:\/\/doi.org\/10.1111\/liv.12078.","journal-title":"Liver Int"},{"key":"2070_CR81","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.virusres.2017.01.003","volume":"244","author":"B Moyo","year":"2018","unstructured":"Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P. Advances with using CRISPR\/Cas-mediated gene editing to treat infections with hepatitis\u00a0B virus and hepatitis\u00a0C virus. Virus Res. 2018;244:311\u201320. https:\/\/doi.org\/10.1016\/j.virusres.2017.01.003.","journal-title":"Virus Res"},{"key":"2070_CR82","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","volume":"476","author":"EM Kennedy","year":"2015","unstructured":"Kennedy EM, Bassit LC, Mueller H, et al. Suppression of hepatitis\u00a0B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease. Virology. 2015;476:196\u2013205. https:\/\/doi.org\/10.1016\/j.virol.2014.12.001.","journal-title":"Virology"},{"key":"2070_CR83","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31008","volume":"72","author":"MF Yuen","year":"2020","unstructured":"Yuen MF, Schiefke I, Yoon JH, et al. RNA interference therapy with ARC-520 results in prolonged hepatitis\u00a0B surface antigen response in patients with chronic hepatitis\u00a0B infection. Hepatology. 2020;72:19\u201331. https:\/\/doi.org\/10.1002\/hep.31008.","journal-title":"Hepatology"},{"key":"2070_CR84","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/liv.14364","volume":"40","author":"MVF Martinez","year":"2020","unstructured":"Martinez MVF, Testoni B, Zoulim F. Can we cure hepatitis\u00a0B virus with novel direct-acting antivirals? Liver Int. 2020;40:27\u201334. https:\/\/doi.org\/10.1111\/liv.14364.","journal-title":"Liver Int"},{"key":"2070_CR85","unstructured":"Man-Fung Y, Tarik A, Ira MJ, et al. Efficacy and safety of the siRNA JNJ-3989 and\/or the capsid assembly modulator JNJ-6379 for the treatment of chronic hepatitis\u00a0B virus infection: results from the phase 2b REEF-1 study. AASLD, 2021 Nov 12\u201315."},{"key":"2070_CR86","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cld.2019.04.006","volume":"23","author":"U Lopatin","year":"2019","unstructured":"Lopatin U. Drugs in the pipeline for HBV. Clin Liver Dis. 2019;23:535\u201355. https:\/\/doi.org\/10.1016\/j.cld.2019.04.006.","journal-title":"Clin Liver Dis"},{"key":"2070_CR87","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","volume":"65","author":"A Blank","year":"2016","unstructured":"Blank A, Markert C, Hohmann N, et al. First-inhuman application of the novel hepatitis\u00a0B and hepatitis\u00a0D virus entry inhibitor myrcludex B. J Hepatol. 2016;65:483\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.013.","journal-title":"J Hepatol"},{"key":"2070_CR88","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis\u00a0B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827\u201344. https:\/\/doi.org\/10.1038\/s41573-019-0037-0.","journal-title":"Nat Rev Drug Discov"},{"key":"2070_CR89","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","volume":"5","author":"MF Yuen","year":"2020","unstructured":"Yuen MF, Agarwal K, Gane EJ, et al. Safety, pharmacokinetics, and antiviral effects of ABIH0731, a hepatitis\u00a0B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020;5:152\u201366. https:\/\/doi.org\/10.1016\/S2468-1253(19)30346-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2070_CR90","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1016\/S0618-8278(19)30934-X","volume":"70","author":"O Lenz","year":"2019","unstructured":"Lenz O, Verbinnen T, Hodari M, et al. FRI-189-HBcrAg decline in JNJ-56136379-treated chronic hepatitis\u00a0B patients: results of a phase 1 study (FRI-189). J Hepatol. 2019;70:e473\u20134.","journal-title":"J Hepatol"},{"key":"2070_CR91","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","volume":"156","author":"MF Yuen","year":"2019","unstructured":"Yuen MF, Gane EJ, Kim DJ, et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3\u2013778 in patients with chronic HBV infection. Gastroenterology. 2019;156:1392\u2013403. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.023.","journal-title":"Gastroenterology"},{"key":"2070_CR92","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","volume":"5","author":"A Vaillant","year":"2019","unstructured":"Vaillant A. REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection. ACS Infect Dis. 2019;5:675\u201387. https:\/\/doi.org\/10.1021\/acsinfecdis.8b00156.","journal-title":"ACS Infect Dis"},{"key":"2070_CR93","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","volume":"144","author":"RE Lanford","year":"2013","unstructured":"Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis\u00a0B virus in chronically infected chimpanzees. Gastroenterology. 2013;144:1508\u201317. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.003.","journal-title":"Gastroenterology"},{"key":"2070_CR94","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/jvh.12942","volume":"25","author":"KAS Agarwal","year":"2018","unstructured":"Agarwal KAS, Elkashab M, Kim K, et al. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis\u00a0B who are not currently on antiviral treatment. J Viral Hepatol. 2018;25:1331\u201340. https:\/\/doi.org\/10.1111\/jvh.12942.","journal-title":"J Viral Hepatol"},{"key":"2070_CR95","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S0168-8278(17)30315-X","volume":"66","author":"E Gane","year":"2017","unstructured":"Gane E, Gaggar A, Nguyen AH, et al. A phase 1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis\u00a0B patients. J Hepatol. 2017;66:S26\u20137. https:\/\/doi.org\/10.1016\/S0168-8278(17)30315-X.","journal-title":"J Hepatol"},{"key":"2070_CR96","doi-asserted-by":"publisher","first-page":"e00771","DOI":"10.1128\/AAC.00771-17","volume":"61","author":"F Guo","year":"2017","unstructured":"Guo F, Tang L, Shu S, et al. Activation of STING in hepatocytes suppresses the replication of hepatitis\u00a0B virus. Antimicrob Agents Chemother. 2017;61:e00771-e817. https:\/\/doi.org\/10.1128\/AAC.00771-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"2070_CR97","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","volume":"65","author":"AS Lok","year":"2016","unstructured":"Lok AS, Pan CQ, Han SH, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis\u00a0B. J Hepatol. 2016;65:509\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.016.","journal-title":"J Hepatol"},{"key":"2070_CR98","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/s0264-410x(00)00410-2","volume":"19","author":"P Rendi-Wagner","year":"2001","unstructured":"Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibody-response to three recombinant hepatitis\u00a0B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine. 2001;19:2055\u201360. https:\/\/doi.org\/10.1016\/s0264-410x(00)00410-2.","journal-title":"Vaccine"},{"key":"2070_CR99","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.3748\/wjg.v20.i29.9633","volume":"20","author":"F Ansaldi","year":"2014","unstructured":"Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis\u00a0C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014;20:9633\u201352. https:\/\/doi.org\/10.3748\/wjg.v20.i29.9633.","journal-title":"World J Gastroenterol"},{"key":"2070_CR100","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis\u00a0C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376. https:\/\/doi.org\/10.1016\/S2468-1253(16)30181-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2070_CR101","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7326\/M16-2350","volume":"166","author":"KN Ly","year":"2017","unstructured":"Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. Hepatitis\u00a0C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med. 2017;166:775\u201382. https:\/\/doi.org\/10.7326\/M16-2350.","journal-title":"Ann Intern Med"},{"issue":"1 Suppl","key":"2070_CR102","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jhep.2005.11.005","volume":"44","author":"JM Pawlotsky","year":"2006","unstructured":"Pawlotsky JM. Virology of hepatitis\u00a0B and C viruses and antiviral targets. J Hepatol. 2006;44(1 Suppl):S10-13. https:\/\/doi.org\/10.1016\/j.jhep.2005.11.005.","journal-title":"J Hepatol"},{"key":"2070_CR103","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJM199212313272702","volume":"327","author":"MJ Alter","year":"1992","unstructured":"Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis\u00a0C in the United States. The sentinel counties chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899\u2013905. https:\/\/doi.org\/10.1056\/NEJM199212313272702.","journal-title":"N Engl J Med"},{"key":"2070_CR104","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis\u00a0C virus genotypes. Hepatology. 2015;61:77\u201387. https:\/\/doi.org\/10.1002\/hep.27259.","journal-title":"Hepatology"},{"key":"2070_CR105","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1086\/591699","volume":"47","author":"S Aaron","year":"2008","unstructured":"Aaron S, McMahon JM, Milano D, et al. Intranasal transmission of hepatitis\u00a0C virus: virological and clinical evidence. Clin Infect Dis. 2008;47:931\u20134. https:\/\/doi.org\/10.1086\/591699.","journal-title":"Clin Infect Dis"},{"key":"2070_CR106","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/AOG.0000000000001507","volume":"128","author":"N Fernandez","year":"2016","unstructured":"Fernandez N, Towers CV, Wolfe L, Hennessy MD, Weitz B, Porter S. Sharing of snorting straws and hepatitis\u00a0C virus infection in pregnant women. Obstet Gynecol. 2016;128:234\u20137. https:\/\/doi.org\/10.1097\/AOG.0000000000001507.","journal-title":"Obstet Gynecol"},{"key":"2070_CR107","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00062752-200311000-00003","volume":"10","author":"GJ Pomper","year":"2003","unstructured":"Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol. 2003;10:412\u20138. https:\/\/doi.org\/10.1097\/00062752-200311000-00003.","journal-title":"Curr Opin Hematol"},{"key":"2070_CR108","doi-asserted-by":"publisher","first-page":"e99677","DOI":"10.1371\/journal.pone.0099677","volume":"9","author":"J Pepin","year":"2014","unstructured":"Pepin J, Abou Chakra CN, Pepin E, Nault V, Valiquette L. Evolution of the global burden of viral infections from unsafe medical injections, 2000\u201310. PLoS\u00a0One. 2014;9:e99677. https:\/\/doi.org\/10.1371\/journal.pone.0099677.","journal-title":"PLoS\u00a0One"},{"key":"2070_CR109","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJM199108153250702","volume":"325","author":"BJ Pereira","year":"1991","unstructured":"Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis\u00a0C virus by organ transplantation. N Engl J Med. 1991;325:454\u201360. https:\/\/doi.org\/10.1056\/NEJM199108153250702.","journal-title":"N Engl J Med"},{"key":"2070_CR110","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1111\/j.1572-0241.2001.05267.x","volume":"96","author":"T Stroffolini","year":"2001","unstructured":"Stroffolini T, Lorenzoni U, Menniti-Ippolito F, Infantolino D, Chiaramonte M. Hepatitis\u00a0C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol. 2001;96:3138\u201341. https:\/\/doi.org\/10.1111\/j.1572-0241.2001.05267.x.","journal-title":"Am J Gastroenterol"},{"key":"2070_CR111","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199908193410802","volume":"341","author":"MJ Alter","year":"1999","unstructured":"Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis\u00a0C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556\u201362. https:\/\/doi.org\/10.1056\/NEJM199908193410802.","journal-title":"N Engl J Med"},{"key":"2070_CR112","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.23808","volume":"52","author":"RA Tohme","year":"2010","unstructured":"Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis\u00a0C virus transmission? Hepatology. 2010;52:1497\u2013505. https:\/\/doi.org\/10.1002\/hep.23808.","journal-title":"Hepatology"},{"key":"2070_CR113","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/cid\/ciu447","volume":"59","author":"L Benova","year":"2014","unstructured":"Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis\u00a0C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59:765\u201373. https:\/\/doi.org\/10.1093\/cid\/ciu447.","journal-title":"Clin Infect Dis"},{"key":"2070_CR114","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5301\/ijao.5000437","volume":"38","author":"F Fabrizi","year":"2015","unstructured":"Fabrizi F, Messa P. Transmission of hepatitis\u00a0C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38:471\u201380. https:\/\/doi.org\/10.5301\/ijao.5000437.","journal-title":"Int J Artif Organs"},{"key":"2070_CR115","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/S2468-1253(17)30249-2","volume":"2","author":"MW Sonderup","year":"2017","unstructured":"Sonderup MW, Afihene M, Ally R, et al. Hepatitis\u00a0C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. Lancet Gastroenterol Hepatol. 2017;2:910\u20139. https:\/\/doi.org\/10.1016\/S2468-1253(17)30249-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2070_CR116","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","volume":"394","author":"CW Spearman","year":"2019","unstructured":"Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis\u00a0C. Lancet. 2019;394:1451\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(19)32320-7.","journal-title":"Lancet"},{"key":"2070_CR117","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.gtc.2015.07.003","volume":"44","author":"S Lingala","year":"2015","unstructured":"Lingala S, Ghany MG. Natural history of hepatitis\u00a0C. Gastroenterol Clin N Am. 2015;44:717\u201334. https:\/\/doi.org\/10.1016\/j.gtc.2015.07.003.","journal-title":"Gastroenterol Clin N Am"},{"key":"2070_CR118","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0168-8278(02)00387-2","volume":"38","author":"JP Zarski","year":"2003","unstructured":"Zarski JP, Mc Hutchison J, Bronowicki JP, et al. Rate of natural disease progression in patients with chronic hepatitis\u00a0C. J Hepatol. 2003;38:307\u201314. https:\/\/doi.org\/10.1016\/s0168-8278(02)00387-2.","journal-title":"J Hepatol"},{"key":"2070_CR119","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7326\/0003-4819-132-2-200001180-00003","volume":"132","author":"LB Seeff","year":"2000","unstructured":"Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis\u00a0C virus infection in healthy young adults. Ann Intern Med. 2000;132:105\u201311. https:\/\/doi.org\/10.7326\/0003-4819-132-2-200001180-00003.","journal-title":"Ann Intern Med"},{"key":"2070_CR120","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/hep.510290424","volume":"29","author":"KQ Hu","year":"1999","unstructured":"Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis\u00a0C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29:1311\u20136. https:\/\/doi.org\/10.1002\/hep.510290424.","journal-title":"Hepatology"},{"key":"2070_CR121","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type\u00a0C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463\u201372. https:\/\/doi.org\/10.1053\/gast.1997.v112.pm9024300.","journal-title":"Gastroenterology"},{"key":"2070_CR122","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hep.29115","volume":"66","author":"DJT Bruden","year":"2017","unstructured":"Bruden DJT, McMahon BJ, Townshend-Bulson L, et al. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis\u00a0C Alaska Cohort. Hepatology. 2017;66:37\u201345. https:\/\/doi.org\/10.1002\/hep.29115.","journal-title":"Hepatology"},{"key":"2070_CR123","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.24503","volume":"54","author":"F Marabita","year":"2011","unstructured":"Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis\u00a0C and known date of infection. Hepatology. 2011;54:1127\u201334. https:\/\/doi.org\/10.1002\/hep.24503.","journal-title":"Hepatology"},{"issue":"3 Suppl 1","key":"2070_CR124","doi-asserted-by":"publisher","first-page":"21S","DOI":"10.1002\/hep.510260704","volume":"26","author":"LB Seeff","year":"1997","unstructured":"Seeff LB. Natural history of hepatitis\u00a0C. Hepatology. 1997;26(3 Suppl 1):21S-28S. https:\/\/doi.org\/10.1002\/hep.510260704.","journal-title":"Hepatology"},{"key":"2070_CR125","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","volume":"125","author":"JM Hui","year":"2003","unstructured":"Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis\u00a0C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125:1695\u2013704. https:\/\/doi.org\/10.1053\/j.gastro.2003.08.032.","journal-title":"Gastroenterology"},{"issue":"Suppl 5","key":"2070_CR126","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","volume":"46","author":"P Cacoub","year":"2014","unstructured":"Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis\u00a0C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165\u201373. https:\/\/doi.org\/10.1016\/j.dld.2014.10.005.","journal-title":"Dig Liver Dis"},{"key":"2070_CR127","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/ki.1997.139","volume":"51","author":"BJ Pereira","year":"1997","unstructured":"Pereira BJ, Levey AS. Hepatitis\u00a0C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51:981\u201399. https:\/\/doi.org\/10.1038\/ki.1997.139.","journal-title":"Kidney Int"},{"key":"2070_CR128","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/hep.1840210306","volume":"21","author":"JM Barrera","year":"1995","unstructured":"Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis\u00a0C viremia after acute self-limiting posttransfusion hepatitis\u00a0C. Hepatology. 1995;21:639\u201344.","journal-title":"Hepatology"},{"key":"2070_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","volume":"69","author":"S Schillie","year":"2020","unstructured":"Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis\u00a0C screening among adults\u2014United States, 2020. MMWR Recomm Rep. 2020;69:1\u201317. https:\/\/doi.org\/10.15585\/mmwr.rr6902a1.","journal-title":"MMWR Recomm Rep"},{"key":"2070_CR130","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis\u00a0C 2018. J Hepatol. 2018;69:461\u2013511. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026.","journal-title":"J Hepatol"},{"key":"2070_CR131","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","volume":"17","author":"K Deterding","year":"2017","unstructured":"Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis\u00a0C virus genotype\u00a01 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017;17:215\u201322. https:\/\/doi.org\/10.1016\/S1473-3099(16)30408-X.","journal-title":"Lancet Infect Dis"},{"issue":"5 Pt 1","key":"2070_CR132","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis\u00a0C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329\u201337. https:\/\/doi.org\/10.7326\/0003-4819-158-5-201303050-00005.","journal-title":"Ann Intern Med"},{"key":"2070_CR133","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"T Poynard","year":"2002","unstructured":"Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis\u00a0C. Gastroenterology. 2002;122:1303\u201313. https:\/\/doi.org\/10.1053\/gast.2002.33023.","journal-title":"Gastroenterology"},{"key":"2070_CR134","doi-asserted-by":"publisher","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","volume":"147","author":"BJ Veldt","year":"2007","unstructured":"Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis\u00a0C and advanced fibrosis. Ann Intern Med. 2007;147:677\u201384. https:\/\/doi.org\/10.7326\/0003-4819-147-10-200711200-00003.","journal-title":"Ann Intern Med"},{"key":"2070_CR135","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/apt.14823","volume":"48","author":"N Saraiya","year":"2018","unstructured":"Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, Singal AG. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018;48:127\u201337. https:\/\/doi.org\/10.1111\/apt.14823.","journal-title":"Aliment Pharmacol Ther"},{"key":"2070_CR136","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1515\/jtim-2017-0007","volume":"5","author":"A Geddawy","year":"2017","unstructured":"Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis\u00a0C virus drugs: clinical pharmacology and future direction. J Transl Int Med. 2017;5:8\u201317. https:\/\/doi.org\/10.1515\/jtim-2017-0007.","journal-title":"J Transl Int Med"},{"key":"2070_CR137","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/cid\/cix260","volume":"65","author":"D Wyles","year":"2017","unstructured":"Wyles D, Brau N, Kottilil S, et al. Sofosbuvir and velpatasvir for the treatment of hepatitis\u00a0C virus in patients coinfected with human immunodeficiency virus type\u00a01: an open-label, phase 3 study. Clin Infect Dis. 2017;65:6\u201312. https:\/\/doi.org\/10.1093\/cid\/cix260.","journal-title":"Clin Infect Dis"},{"key":"2070_CR138","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype\u00a01, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1512610.","journal-title":"N Engl J Med"},{"key":"2070_CR139","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1512614.","journal-title":"N Engl J Med"},{"key":"2070_CR140","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, et al. Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype\u00a01 or 3 infection. N Engl J Med. 2018;378:354\u201369. https:\/\/doi.org\/10.1056\/NEJMoa1702417.","journal-title":"N Engl J Med"},{"key":"2070_CR141","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jvh.12737","volume":"24","author":"N Kawagishi","year":"2017","unstructured":"Kawagishi N, Suda G, Onozawa M, et al. Comparing the risk of hepatitis\u00a0B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis\u00a0C. J Viral Hepat. 2017;24:1098\u2013106. https:\/\/doi.org\/10.1111\/jvh.12737.","journal-title":"J Viral Hepat"},{"key":"2070_CR142","doi-asserted-by":"publisher","first-page":"124","DOI":"10.14218\/JCTH.2014.00002","volume":"2","author":"C Bunchorntavakul","year":"2014","unstructured":"Bunchorntavakul C, Reddy KR. Management of hepatitis\u00a0C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J Clin Transl Hepatol. 2014;2:124\u201333. https:\/\/doi.org\/10.14218\/JCTH.2014.00002.","journal-title":"J Clin Transl Hepatol"},{"key":"2070_CR143","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/ajt.15768","volume":"20","author":"E Bethea","year":"2020","unstructured":"Bethea E, Arvind A, Gustafson J, et al. Immediate administration of antiviral therapy after transplantation of hepatitis\u00a0C-infected livers into uninfected recipients: implications for therapeutic planning. Am J Transplant. 2020;20:1619\u201328. https:\/\/doi.org\/10.1111\/ajt.15768.","journal-title":"Am J Transplant"},{"key":"2070_CR144","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/lt.25925","volume":"27","author":"H Bohorquez","year":"2021","unstructured":"Bohorquez H, Bugeaud E, Bzowej N, et al. Liver transplantation using hepatitis\u00a0C virus-viremic donors into hepatitis\u00a0C virus-aviremic recipients as standard of care. Liver Transpl. 2021;27:548\u201357. https:\/\/doi.org\/10.1002\/lt.25925.","journal-title":"Liver Transpl"},{"key":"2070_CR145","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1002\/hep.30540","volume":"69","author":"TG Cotter","year":"2019","unstructured":"Cotter TG, Paul S, Sand\u0131k\u00e7\u0131 B, et al. Increasing utilization and excellent initial outcomes following liver transplant of hepatitis\u00a0C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors. Hepatology. 2019;69:2381\u201395. https:\/\/doi.org\/10.1002\/hep.30540.","journal-title":"Hepatology"},{"key":"2070_CR146","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/hep.31551","volume":"73","author":"NA Terrault","year":"2021","unstructured":"Terrault NA, Burton J, Ghobrial M, et al. Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors. Hepatology. 2021;73:2110\u201323. https:\/\/doi.org\/10.1002\/hep.31551.","journal-title":"Hepatology"},{"key":"2070_CR147","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/tri.13410","volume":"32","author":"A Franco","year":"2019","unstructured":"Franco A, Moreso F, Merino E, et al. Renal transplantation from seropositive hepatitis\u00a0C virus donors to seronegative recipients in Spain: a prospective study. Transpl Int. 2019;32:710\u20136. https:\/\/doi.org\/10.1111\/tri.13410.","journal-title":"Transpl Int"},{"key":"2070_CR148","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3748\/wjg.v20.i1.148","volume":"20","author":"Y Amador-Canizares","year":"2014","unstructured":"Amador-Canizares Y, Martinez-Donato G, Alvarez-Lajonchere L, et al. HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin. World J Gastroenterol. 2014;20:148\u201362. https:\/\/doi.org\/10.3748\/wjg.v20.i1.148.","journal-title":"World J Gastroenterol"},{"key":"2070_CR149","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","volume":"28","author":"SE Frey","year":"2010","unstructured":"Frey SE, Houghton M, Coates S, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28:6367\u201373. https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.084.","journal-title":"Vaccine"},{"key":"2070_CR150","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1134\/S0026893310020093","volume":"44","author":"OV Masalova","year":"2010","unstructured":"Masalova OV, Lesnova EI, Grabovetskii VV, et al. [DNA immunization with a plasmid containing gene of hepatitis\u00a0C virus protein 5A (NS5A) induces the effective cellular immune response]. Mol Biol (Mosk). 2010;44:275\u201383.","journal-title":"Mol Biol (Mosk)"},{"key":"2070_CR151","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","volume":"156","author":"JR Bailey","year":"2019","unstructured":"Bailey JR, Barnes E, Cox AL. Approaches, progress, and challenges to hepatitis\u00a0C vaccine development. Gastroenterology. 2019;156:418\u201330. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.060.","journal-title":"Gastroenterology"},{"key":"2070_CR152","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/gut.18.12.997","volume":"18","author":"M Rizzetto","year":"1977","unstructured":"Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis\u00a0B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997\u20131003. https:\/\/doi.org\/10.1136\/gut.18.12.997.","journal-title":"Gut"},{"issue":"3","key":"2070_CR153","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis\u00a0D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.008.","journal-title":"J Hepatol"},{"key":"2070_CR154","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000431040","volume":"58","author":"LF Botelho-Souza","year":"2015","unstructured":"Botelho-Souza LF, SouzaVieira D, de OliveiraDosSantos A, CunhaPereira AV, Villalobos-Salcedo JM. Characterization of the genotypic profile of hepatitis delta virus: isolation of HDV genotype-1 in the western Amazon Region of Brazil. Intervirology. 2015;58:166\u201371. https:\/\/doi.org\/10.1159\/000431040.","journal-title":"Intervirology"},{"key":"2070_CR155","first-page":"94","volume":"3","author":"V Bichko","year":"1994","unstructured":"Bichko V, Netter HJ, Wu TT, Taylor J. Pathogenesis associated with replication of hepatitis delta virus. Infect Agents Dis. 1994;3:94\u20137.","journal-title":"Infect Agents Dis"},{"key":"2070_CR156","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1128\/mcb.20.16.6030-6039.2000","volume":"20","author":"LE Modahl","year":"2000","unstructured":"Modahl LE, Macnaughton TB, Zhu N, Johnson DL, Lai MM. RNA-dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol Cell Biol. 2000;20:6030\u20139. https:\/\/doi.org\/10.1128\/mcb.20.16.6030-6039.2000.","journal-title":"Mol Cell Biol"},{"key":"2070_CR157","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1128\/JVI.58.3.945-950.1986","volume":"58","author":"F Bonino","year":"1986","unstructured":"Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis\u00a0B virus-derived envelope. J Virol. 1986;58:945\u201350. https:\/\/doi.org\/10.1128\/JVI.58.3.945-950.1986.","journal-title":"J Virol"},{"key":"2070_CR158","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1055\/s-0032-1323628","volume":"32","author":"P Farci","year":"2012","unstructured":"Farci P, Niro GA. Clinical features of hepatitis\u00a0D. Semin Liver Dis. 2012;32:228\u201336. https:\/\/doi.org\/10.1055\/s-0032-1323628.","journal-title":"Semin Liver Dis"},{"issue":"Suppl 4","key":"2070_CR159","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/0168-8278(91)90040-i","volume":"13","author":"M Rizzetto","year":"1991","unstructured":"Rizzetto M, Durazzo M. Hepatitis delta virus (HDV) infections. Epidemiol Clin Heterogeneit J Hepatol. 1991;13(Suppl 4):S116\u20138. https:\/\/doi.org\/10.1016\/0168-8278(91)90040-i.","journal-title":"Epidemiol Clin Heterogeneit J Hepatol"},{"key":"2070_CR160","first-page":"245","volume":"143","author":"F Caredda","year":"1983","unstructured":"Caredda F, d\u2019Arminio Monforte A, Rossi E, et al. Prospective study of epidemic delta infection in drug addicts. Prog Clin Biol Res. 1983;143:245\u201350.","journal-title":"Prog Clin Biol Res"},{"key":"2070_CR161","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/gut.46.3.420","volume":"46","author":"G Fattovich","year":"2000","unstructured":"Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type\u00a0B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46:420\u20136. https:\/\/doi.org\/10.1136\/gut.46.3.420.","journal-title":"Gut"},{"key":"2070_CR162","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/hep.1840140105","volume":"14","author":"R Jardi","year":"1991","unstructured":"Jardi R, Buti M, Rodriguez-Frias F, et al. Clinical significance of two forms of IgM antibody to hepatitis delta virus. Hepatology. 1991;14:25\u20138. https:\/\/doi.org\/10.1002\/hep.1840140105.","journal-title":"Hepatology"},{"key":"2070_CR163","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0166-0934(94)90163-5","volume":"50","author":"R Jardi","year":"1994","unstructured":"Jardi R, Buti M, Rodriguez F, et al. Comparative analysis of serological markers of chronic delta infection: HDV-RNA, serum HDAg and anti-HD IgM. J Virol Methods. 1994;50:59\u201366. https:\/\/doi.org\/10.1016\/0166-0934(94)90163-5.","journal-title":"J Virol Methods"},{"key":"2070_CR164","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1055\/s-0032-1323629","volume":"32","author":"C Yurdaydin","year":"2012","unstructured":"Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:237\u201344. https:\/\/doi.org\/10.1055\/s-0032-1323629.","journal-title":"Semin Liver Dis"},{"key":"2070_CR165","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/apt.12788","volume":"40","author":"T Heller","year":"2014","unstructured":"Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40:93\u2013104. https:\/\/doi.org\/10.1111\/apt.12788.","journal-title":"Aliment Pharmacol Ther"},{"key":"2070_CR166","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.21296","volume":"44","author":"GA Niro","year":"2006","unstructured":"Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713\u201320. https:\/\/doi.org\/10.1002\/hep.21296.","journal-title":"Hepatology"},{"key":"2070_CR167","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","volume":"15","author":"C Yurdaydin","year":"2008","unstructured":"Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15:314\u201321. https:\/\/doi.org\/10.1111\/j.1365-2893.2007.00936.x.","journal-title":"J Viral Hepat"},{"issue":"461\u201376","key":"2070_CR168","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.09.058","volume":"156","author":"C Koh","year":"2019","unstructured":"Koh C, Heller T, Glenn JS. Pathogenesis of and new therapies for hepatitis\u00a0D. Gastroenterology. 2019;156(461\u201376): e461. https:\/\/doi.org\/10.1053\/j.gastro.2018.09.058.","journal-title":"Gastroenterology"},{"key":"2070_CR169","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","volume":"70","author":"C Yurdaydin","year":"2019","unstructured":"Yurdaydin C, Abbas Z, Buti M, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol. 2019;70:1008\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2018.12.022.","journal-title":"J Hepatol"},{"key":"2070_CR170","doi-asserted-by":"publisher","first-page":"9303","DOI":"10.1128\/JVI.72.11.9303-9306.1998","volume":"72","author":"JS Glenn","year":"1998","unstructured":"Glenn JS, Marsters JC Jr, Greenberg HB. Use of a prenylation inhibitor as a novel antiviral agent. J Virol. 1998;72:9303\u20136. https:\/\/doi.org\/10.1128\/JVI.72.11.9303-9306.1998.","journal-title":"J Virol"},{"key":"2070_CR171","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis\u00a0D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15:1167\u201374. https:\/\/doi.org\/10.1016\/S1473-3099(15)00074-2.","journal-title":"Lancet Infect Dis"},{"key":"2070_CR172","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/hep.29658","volume":"67","author":"C Yurdaydin","year":"2018","unstructured":"Yurdaydin C, Keskin O, Kalkan C, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018;67:1224\u201336. https:\/\/doi.org\/10.1002\/hep.29658.","journal-title":"Hepatology"},{"key":"2070_CR173","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S0168-8278(17)30327-6","volume":"66","author":"C Yurdaydin","year":"2017","unstructured":"Yurdaydin C, Idilman R, Kalkan C, et al. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study. J Hepatol. 2017;66:S33\u20134.","journal-title":"J Hepatol"},{"key":"2070_CR174","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"P Bogomolov","year":"2016","unstructured":"Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis\u00a0D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study. J Hepatol. 2016;65:490\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.016.","journal-title":"J Hepatol"},{"key":"2070_CR175","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","volume":"68","author":"H Wedemeyer","year":"2018","unstructured":"Wedemeyer H, Bogomolov P, Blank A, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with HBV\/HDV coinfection. J Hepatol. 2018;68:S3. https:\/\/doi.org\/10.1016\/S0168-8278(18)30224-1.","journal-title":"J Hepatol"},{"key":"2070_CR176","first-page":"496A","volume":"66","author":"S Hamid","year":"2017","unstructured":"Hamid S, Etzion O, Lurie Y, et al. A phase 2 randomized clinical trial to evaluate the safety and efficacy of pegylated intereron lambda monotherapy in patients with chronic hepatitis delta virus infection. Interim results from the LIMT HDV study. Hepatology. 2017;66:496A.","journal-title":"Hepatology"},{"key":"2070_CR177","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","volume":"2","author":"M Bazinet","year":"2017","unstructured":"Bazinet M, Pantea V, Cebotarescu V, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis\u00a0B virus and hepatitis\u00a0D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2:877\u201389. https:\/\/doi.org\/10.1016\/S2468-1253(17)30288-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2070_CR178","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/0002-9343(80)90200-4","volume":"68","author":"MS Khuroo","year":"1980","unstructured":"Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med. 1980;68:818\u201324. https:\/\/doi.org\/10.1016\/0002-9343(80)90200-4.","journal-title":"Am J Med"},{"key":"2070_CR179","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/apt.14109","volume":"46","author":"MC Donnelly","year":"2017","unstructured":"Donnelly MC, Scobie L, Crossan CL, Dalton H, Hayes PC, Simpson KJ. Review article: hepatitis\u00a0E\u2014a concise review of virology, epidemiology, clinical presentation and therapy. Aliment Pharmacol Ther. 2017;46:126\u201341. https:\/\/doi.org\/10.1111\/apt.14109.","journal-title":"Aliment Pharmacol Ther"},{"key":"2070_CR180","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/S0140-6736(11)61849-7","volume":"379","author":"N Kamar","year":"2012","unstructured":"Kamar N, Bendall R, Legrand-Abravanel F, et al. Lancet. 2012;379:2477\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(11)61849-7.","journal-title":"Lancet"},{"key":"2070_CR181","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.3748\/wjg.v26.i37.5543","volume":"26","author":"AT Aslan","year":"2020","unstructured":"Aslan AT, Balaban HY. Hepatitis\u00a0E virus: epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol. 2020;26:5543\u201360. https:\/\/doi.org\/10.3748\/wjg.v26.i37.5543.","journal-title":"World J Gastroenterol"},{"key":"2070_CR182","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/0042-6822(91)90760-9","volume":"185","author":"AW Tam","year":"1991","unstructured":"Tam AW, Smith MM, Guerra ME, et al. Hepatitis\u00a0E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology. 1991;185:120\u201331. https:\/\/doi.org\/10.1016\/0042-6822(91)90760-9.","journal-title":"Virology"},{"key":"2070_CR183","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/rmv.384","volume":"13","author":"SU Emerson","year":"2003","unstructured":"Emerson SU, Purcell RH. Hepatitis\u00a0E virus. Rev Med Virol. 2003;13:145\u201354. https:\/\/doi.org\/10.1002\/rmv.384.","journal-title":"Rev Med Virol"},{"key":"2070_CR184","first-page":"597","volume":"70","author":"SR Naik","year":"1992","unstructured":"Naik SR, Aggarwal R, Salunke PN, Mehrotra NN. A large waterborne viral hepatitis\u00a0E epidemic in Kanpur. India Bull World Health Organ. 1992;70:597\u2013604.","journal-title":"India Bull World Health Organ"},{"key":"2070_CR185","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijerph10104507","volume":"10","author":"DM Yugo","year":"2013","unstructured":"Yugo DM, Meng XJ. Hepatitis\u00a0E virus: foodborne, waterborne and zoonotic transmission. Int J Environ Res Public Health. 2013;10:4507\u201333. https:\/\/doi.org\/10.3390\/ijerph10104507.","journal-title":"Int J Environ Res Public Health"},{"key":"2070_CR186","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13567-014-0121-8","volume":"45","author":"J Schlosser","year":"2014","unstructured":"Schlosser J, Eiden M, Vina-Rodriguez A, et al. Natural and experimental hepatitis\u00a0E virus genotype\u00a03-infection in European wild boar is transmissible to domestic pigs. Vet Res. 2014;45:121. https:\/\/doi.org\/10.1186\/s13567-014-0121-8.","journal-title":"Vet Res"},{"key":"2070_CR187","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3201\/eid1808.120057","volume":"18","author":"J Izopet","year":"2012","unstructured":"Izopet J, Dubois M, Bertagnoli S, et al. Hepatitis\u00a0E virus strains in rabbits and evidence of a closely related strain in humans, France. Emerg Infect Dis. 2012;18:1274\u201381. https:\/\/doi.org\/10.3201\/eid1808.120057.","journal-title":"Emerg Infect Dis"},{"key":"2070_CR188","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/S0140-6736(14)61034-5","volume":"384","author":"PE Hewitt","year":"2014","unstructured":"Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis\u00a0E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384:1766\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(14)61034-5.","journal-title":"Lancet"},{"key":"2070_CR189","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/trf.12121","volume":"54","author":"D Juhl","year":"2014","unstructured":"Juhl D, Baylis SA, Blumel J, Gorg S, Hennig H. Seroprevalence and incidence of hepatitis\u00a0E virus infection in German blood donors. Transfusion. 2014;54:49\u201356. https:\/\/doi.org\/10.1111\/trf.12121.","journal-title":"Transfusion"},{"key":"2070_CR190","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/trf.13876","volume":"57","author":"M Riveiro-Barciela","year":"2017","unstructured":"Riveiro-Barciela M, Sauleda S, Quer J, et al. Red blood cell transfusion-transmitted acute hepatitis\u00a0E in an immunocompetent subject in Europe: a case report. Transfusion. 2017;57:244\u20137. https:\/\/doi.org\/10.1111\/trf.13876.","journal-title":"Transfusion"},{"key":"2070_CR191","first-page":"199","volume":"3","author":"G Nicaise","year":"1989","unstructured":"Nicaise G, Gillot I, Julliard AK, et al. X-ray microanalysis of calcium containing organelles in resin embedded tissue. Scan Microsc. 1989;3:199\u2013219 (discussion 219\u2013120).","journal-title":"Scan Microsc"},{"key":"2070_CR192","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/ijmm.IJMM_18_149","volume":"36","author":"E Gupta","year":"2018","unstructured":"Gupta E, Agarwala P. Hepatitis\u00a0E virus infection: an old virus with a new story! Indian J Med Microbiol. 2018;36:317\u201323. https:\/\/doi.org\/10.4103\/ijmm.IJMM_18_149.","journal-title":"Indian J Med Microbiol"},{"key":"2070_CR193","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0140-6736(93)90008-5","volume":"341","author":"A Chauhan","year":"1993","unstructured":"Chauhan A, Jameel S, Dilawari JB, Chawla YK, Kaur U, Ganguly NK. Hepatitis\u00a0E virus transmission to a volunteer. Lancet. 1993;341:149\u201350. https:\/\/doi.org\/10.1016\/0140-6736(93)90008-5.","journal-title":"Lancet"},{"key":"2070_CR194","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000149370","volume":"20","author":"MS Balayan","year":"1983","unstructured":"Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20:23\u201331. https:\/\/doi.org\/10.1159\/000149370.","journal-title":"Intervirology"},{"key":"2070_CR195","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA van Doorn","year":"2008","unstructured":"van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008;7:939\u201350. https:\/\/doi.org\/10.1016\/S1474-4422(08)70215-1.","journal-title":"Lancet Neurol"},{"key":"2070_CR196","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1212\/WNL.0000000000000111","volume":"82","author":"B van den Berg","year":"2014","unstructured":"van den Berg B, van der Eijk AA, Pas SD, et al. Guillain-Barre syndrome associated with preceding hepatitis\u00a0E virus infection. Neurology. 2014;82:491\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000000111.","journal-title":"Neurology"},{"key":"2070_CR197","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/cid\/cit512","volume":"57","author":"CH Geurtsvankessel","year":"2013","unstructured":"Geurtsvankessel CH, Islam Z, Mohammad QD, Jacobs BC, Endtz HP, Osterhaus AD. Hepatitis\u00a0E and Guillain\u2013Barre syndrome. Clin Infect Dis. 2013;57:1369\u201370. https:\/\/doi.org\/10.1093\/cid\/cit512.","journal-title":"Clin Infect Dis"},{"key":"2070_CR198","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/j.1572-0241.1999.01318.x","volume":"94","author":"A Mishra","year":"1999","unstructured":"Mishra A, Saigal S, Gupta R, Sarin SK. Acute pancreatitis associated with viral hepatitis: a report of six cases with review of literature. Am J Gastroenterol. 1999;94:2292\u20135. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01318.x.","journal-title":"Am J Gastroenterol"},{"key":"2070_CR199","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/TP.0b013e318245f14c","volume":"93","author":"N Kamar","year":"2012","unstructured":"Kamar N, Weclawiak H, Guilbeau-Frugier C, et al. Hepatitis\u00a0E virus and the kidney in solid-organ transplant patients. Transplantation. 2012;93:617\u201323. https:\/\/doi.org\/10.1097\/TP.0b013e318245f14c.","journal-title":"Transplantation"},{"key":"2070_CR200","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jhep.2016.11.016","volume":"66","author":"S Pischke","year":"2017","unstructured":"Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis\u00a0E virus: infection beyond the liver? J Hepatol. 2017;66:1082\u201395. https:\/\/doi.org\/10.1016\/j.jhep.2016.11.016.","journal-title":"J Hepatol"},{"key":"2070_CR201","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1055\/s-0033-1338112","volume":"33","author":"R Aggarwal","year":"2013","unstructured":"Aggarwal R. Hepatitis\u00a0E: clinical presentation in disease-endemic areas and diagnosis. Semin Liver Dis. 2013;33:30\u201340. https:\/\/doi.org\/10.1055\/s-0033-1338112.","journal-title":"Semin Liver Dis"},{"key":"2070_CR202","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1440-1746.2007.04913.x","volume":"22","author":"N Jilani","year":"2007","unstructured":"Jilani N, Das BC, Husain SA, et al. Hepatitis\u00a0E virus infection and fulminant hepatic failure during pregnancy. J Gastroenterol Hepatol. 2007;22:676\u201382. https:\/\/doi.org\/10.1111\/j.1440-1746.2007.04913.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"2070_CR203","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/0002-9343(81)90758-0","volume":"70","author":"MS Khuroo","year":"1981","unstructured":"Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med. 1981;70:252\u20135. https:\/\/doi.org\/10.1016\/0002-9343(81)90758-0.","journal-title":"Am J Med"},{"key":"2070_CR204","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3201\/eid2109.150300","volume":"21","author":"RB Perumpail","year":"2015","unstructured":"Perumpail RB, Ahmed A, Higgins JP, et al. Fatal accelerated cirrhosis after imported HEV genotype\u00a04 infection. Emerg Infect Dis. 2015;21:1679\u201381. https:\/\/doi.org\/10.3201\/eid2109.150300.","journal-title":"Emerg Infect Dis"},{"key":"2070_CR205","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1111\/j.1600-6143.2012.04200.x","volume":"12","author":"S Pischke","year":"2012","unstructured":"Pischke S, Stiefel P, Franz B, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant. 2012;12:3128\u201333. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04200.x.","journal-title":"Am J Transplant"},{"key":"2070_CR206","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/TP.0b013e3181c4096c","volume":"89","author":"N Kamar","year":"2010","unstructured":"Kamar N, Abravanel F, Selves J, et al. Influence of immunosuppressive therapy on the natural history of genotype\u00a03 hepatitis-E virus infection after organ transplantation. Transplantation. 2010;89:353\u201360. https:\/\/doi.org\/10.1097\/TP.0b013e3181c4096c.","journal-title":"Transplantation"},{"key":"2070_CR207","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1872-034X.2007.00024.x","volume":"37","author":"A Tamura","year":"2007","unstructured":"Tamura A, Shimizu YK, Tanaka T, et al. Persistent infection of hepatitis\u00a0E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res. 2007;37:113\u201320. https:\/\/doi.org\/10.1111\/j.1872-034X.2007.00024.x.","journal-title":"Hepatol Res"},{"key":"2070_CR208","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3201\/eid\/1706.101067","volume":"17","author":"A Kenfak-Foguena","year":"2011","unstructured":"Kenfak-Foguena A, Schoni-Affolter F, Burgisser P, et al. Hepatitis\u00a0E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis. 2011;17:1074\u20138. https:\/\/doi.org\/10.3201\/eid\/1706.101067.","journal-title":"Emerg Infect Dis"},{"key":"2070_CR209","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/ajt.12253","volume":"13","author":"N Kamar","year":"2013","unstructured":"Kamar N, Rostaing L, Legrand-Abravanel F, Izopet J. How should hepatitis\u00a0E virus infection be defined in organ-transplant recipients? Am J Transplant. 2013;13:1935\u20136. https:\/\/doi.org\/10.1111\/ajt.12253.","journal-title":"Am J Transplant"},{"key":"2070_CR210","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s007050070065","volume":"145","author":"KA McCaustland","year":"2000","unstructured":"McCaustland KA, Krawczynski K, Ebert JW, et al. Hepatitis\u00a0E virus infection in chimpanzees: a retrospective analysis. Arch Virol. 2000;145:1909\u201318. https:\/\/doi.org\/10.1007\/s007050070065.","journal-title":"Arch Virol"},{"key":"2070_CR211","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/infdis\/172.4.927","volume":"172","author":"ET Clayson","year":"1995","unstructured":"Clayson ET, Myint KS, Snitbhan R, et al. Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis\u00a0E. J Infect Dis. 1995;172:927\u201333. https:\/\/doi.org\/10.1093\/infdis\/172.4.927.","journal-title":"J Infect Dis"},{"issue":"1388\u201397","key":"2070_CR212","doi-asserted-by":"publisher","first-page":"e1381","DOI":"10.1053\/j.gastro.2012.02.014","volume":"142","author":"H Wedemeyer","year":"2012","unstructured":"Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology. 2012;142(1388\u201397):e1381. https:\/\/doi.org\/10.1053\/j.gastro.2012.02.014.","journal-title":"Gastroenterology"},{"key":"2070_CR213","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/QCO.0000000000000316","volume":"29","author":"HR Dalton","year":"2016","unstructured":"Dalton HR, Kamar N. Treatment of hepatitis\u00a0E virus. Curr Opin Infect Dis. 2016;29:639\u201344. https:\/\/doi.org\/10.1097\/QCO.0000000000000316.","journal-title":"Curr Opin Infect Dis"},{"key":"2070_CR214","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jcv.2011.06.004","volume":"52","author":"R Gerolami","year":"2011","unstructured":"Gerolami R, Borentain P, Raissouni F, Motte A, Solas C, Colson P. Treatment of severe acute hepatitis\u00a0E by ribavirin. J Clin Virol. 2011;52:60\u20132. https:\/\/doi.org\/10.1016\/j.jcv.2011.06.004.","journal-title":"J Clin Virol"},{"key":"2070_CR215","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jhep.2011.01.009","volume":"54","author":"JM Peron","year":"2011","unstructured":"Peron JM, Dalton H, Izopet J, Kamar N. Acute autochthonous hepatitis\u00a0E in western patients with underlying chronic liver disease: a role for ribavirin? J Hepatol. 2011;54:1323\u20134. https:\/\/doi.org\/10.1016\/j.jhep.2011.01.009 (author reply 1324\u20135).","journal-title":"J Hepatol"},{"key":"2070_CR216","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17474124.2019.1568869","volume":"13","author":"P Kar","year":"2019","unstructured":"Kar P, Sengupta A. A guide to the management of hepatitis\u00a0E infection during pregnancy. Expert Rev Gastroenterol Hepatol. 2019;13:205\u201311. https:\/\/doi.org\/10.1080\/17474124.2019.1568869.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2070_CR217","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","volume":"140","author":"N Kamar","year":"2011","unstructured":"Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis\u00a0E virus infection who have received solid organ transplants. Gastroenterology. 2011;140:1481\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.050.","journal-title":"Gastroenterology"},{"key":"2070_CR218","doi-asserted-by":"publisher","first-page":"17086","DOI":"10.1038\/nrdp.2017.86","volume":"3","author":"N Kamar","year":"2017","unstructured":"Kamar N, Izopet J, Pavio N, et al. Hepatitis\u00a0E virus infection. Nat Rev Dis Primers. 2017;3:17086. https:\/\/doi.org\/10.1038\/nrdp.2017.86.","journal-title":"Nat Rev Dis Primers"},{"key":"2070_CR219","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","volume":"370","author":"N Kamar","year":"2014","unstructured":"Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis\u00a0E virus infection in transplant recipients. N Engl J Med. 2014;370:1111\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1215246.","journal-title":"N Engl J Med"},{"key":"2070_CR220","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jvh.12445","volume":"23","author":"MS Khuroo","year":"2016","unstructured":"Khuroo MS, Khuroo MS. Hepatitis\u00a0E: an emerging global disease - from discovery towards control and cure. J Viral Hepat. 2016;23:68\u201379. https:\/\/doi.org\/10.1111\/jvh.12445.","journal-title":"J Viral Hepat"},{"key":"2070_CR221","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1086\/650488","volume":"50","author":"N Kamar","year":"2010","unstructured":"Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis\u00a0E virus infection after liver transplantation. Clin Infect Dis. 2010;50:e30-33. https:\/\/doi.org\/10.1086\/650488.","journal-title":"Clin Infect Dis"},{"key":"2070_CR222","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jhep.2020.05.020","volume":"73","author":"M Cornberg","year":"2020","unstructured":"Cornberg M, Pischke S, M\u00fcller T, et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis\u00a0E\u2014the HepNet SofE pilot study. J Hepatol. 2020;73:696\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.020.","journal-title":"J Hepatol"},{"key":"2070_CR223","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12876-019-0995-z","volume":"19","author":"M Fraga","year":"2019","unstructured":"Fraga M, Gouttenoire J, Sahli R, et al. Sofosbuvir add-on to ribavirin for chronic hepatitis\u00a0E in a cirrhotic liver transplant recipient: a case report. BMC Gastroenterol. 2019;19:76. https:\/\/doi.org\/10.1186\/s12876-019-0995-z.","journal-title":"BMC Gastroenterol"},{"key":"2070_CR224","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jhep.2019.03.029","volume":"71","author":"M Schulz","year":"2019","unstructured":"Schulz M, Papp CP, Bock CT, et al. Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis\u00a0E infection in a multivisceral transplanted patient. J Hepatol. 2019;71:225\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.029.","journal-title":"J Hepatol"},{"key":"2070_CR225","doi-asserted-by":"publisher","first-page":"e00754","DOI":"10.1128\/JVI.00754-17","volume":"91","author":"N Kaushik","year":"2017","unstructured":"Kaushik N, Subramani C, Anang S, et al. Zinc salts block hepatitis\u00a0E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase. J Virol. 2017;91:e00754-e817. https:\/\/doi.org\/10.1128\/JVI.00754-17.","journal-title":"J Virol"},{"key":"2070_CR226","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.antiviral.2018.07.010","volume":"157","author":"D Todt","year":"2018","unstructured":"Todt D, Moeller N, Praditya D, et al. The natural compound silvestrol inhibits hepatitis\u00a0E virus (HEV) replication in vitro and in vivo. Antiviral Res. 2018;157:151\u20138. https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.010.","journal-title":"Antiviral Res"},{"key":"2070_CR227","doi-asserted-by":"publisher","first-page":"e00003","DOI":"10.1128\/AAC.00003-19","volume":"63","author":"NE Netzler","year":"2019","unstructured":"Netzler NE, Enosi Tuipulotu D, Vasudevan SG, Mackenzie JM, White PA. Antiviral candidates for treating hepatitis\u00a0E virus infection. Antimicrob Agents Chemother. 2019;63:e00003-19. https:\/\/doi.org\/10.1128\/AAC.00003-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"2070_CR228","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s00705-017-3444-8","volume":"162","author":"C Qu","year":"2017","unstructured":"Qu C, Xu L, Yin Y, Peppelenbosch MP, Pan Q, Wang W. Nucleoside analogue 2\u2019-C-methylcytidine inhibits hepatitis\u00a0E virus replication but antagonizes ribavirin. Arch Virol. 2017;162:2989\u201396. https:\/\/doi.org\/10.1007\/s00705-017-3444-8.","journal-title":"Arch Virol"},{"key":"2070_CR229","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1056\/NEJMc1504302","volume":"372","author":"J Zhang","year":"2015","unstructured":"Zhang J, Shih JW, Xia NS. Long-term efficacy of a hepatitis\u00a0E vaccine. N Engl J Med. 2015;372:2265\u20136. https:\/\/doi.org\/10.1056\/NEJMc1504302.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02070-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02070-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02070-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:40:32Z","timestamp":1659098432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02070-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,27]]},"references-count":229,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02070-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,27]]},"assertion":[{"value":"16 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}